1. Home
  2. WNC vs IMMP Comparison

WNC vs IMMP Comparison

Compare WNC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WNC

Wabash National Corporation

HOLD

Current Price

$9.10

Market Cap

392.2M

Sector

Industrials

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.76

Market Cap

410.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNC
IMMP
Founded
1985
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
392.2M
410.7M
IPO Year
2009
2012

Fundamental Metrics

Financial Performance
Metric
WNC
IMMP
Price
$9.10
$2.76
Analyst Decision
Hold
Buy
Analyst Count
1
1
Target Price
$11.00
$10.00
AVG Volume (30 Days)
514.3K
163.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
3.55%
N/A
EPS Growth
179.22
N/A
EPS
5.07
N/A
Revenue
$2,027,489,000.00
N/A
Revenue This Year
$0.53
$382.75
Revenue Next Year
$25.53
N/A
P/E Ratio
$1.78
N/A
Revenue Growth
8.81
N/A
52 Week Low
$6.78
$1.32
52 Week High
$12.94
$3.53

Technical Indicators

Market Signals
Indicator
WNC
IMMP
Relative Strength Index (RSI) 32.52 49.22
Support Level $8.41 $2.74
Resistance Level $9.39 $3.24
Average True Range (ATR) 0.47 0.13
MACD -0.21 -0.01
Stochastic Oscillator 11.37 53.22

Price Performance

Historical Comparison
WNC
IMMP

About WNC Wabash National Corporation

Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: